PMD Fundamental Analysis - PSYCHEMEDICS CORP

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PMD. PMD was compared to 101 industry peers in the Health Care Providers & Services industry. While PMD seems to be doing ok healthwise, there are quite some concerns on its profitability. PMD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PMD had negative earnings in the past year.

In the past year PMD had a positive cash flow from operations.

PMD had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: PMD reported negative operating cash flow in multiple years.

1.2 Ratios

PMD has a Return On Assets of -30.45%. This is amonst the worse of the industry: PMD underperforms 84.26% of its industry peers.

Looking at the Return On Equity, with a value of -54.99%, PMD is doing worse than 69.44% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-30.45%
ROE	-54.99%
ROIC	N/A

ROA(3y)-14.19%

ROA(5y)-10.61%

ROE(3y)-25.92%

ROE(5y)-19.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PMD's Gross Margin of 38.36% is fine compared to the rest of the industry. PMD outperforms 64.81% of its industry peers.

PMD's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for PMD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	38.36%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y18.48%

GM growth 5Y-4.66%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PMD does not have a ROIC to compare to the WACC, probably because it is not profitable.

PMD has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, PMD has more shares outstanding

Compared to 1 year ago, PMD has an improved debt to assets ratio.

2.2 Solvency

PMD has an Altman-Z score of 0.82. This is a bad value and indicates that PMD is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of PMD (0.82) is worse than 66.67% of its industry peers.

The Debt to FCF ratio of PMD is 1.21, which is an excellent value as it means it would take PMD, only 1.21 years of fcf income to pay off all of its debts.

With an excellent Debt to FCF ratio value of 1.21, PMD belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.

A Debt/Equity ratio of 0.09 indicates that PMD is not too dependend on debt financing.

PMD has a better Debt to Equity ratio (0.09) than 74.07% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	1.21
Altman-Z	0.82

ROIC/WACCN/A

WACC9.04%

2.3 Liquidity

A Current Ratio of 1.59 indicates that PMD should not have too much problems paying its short term obligations.

The Current ratio of PMD (1.59) is better than 60.19% of its industry peers.

PMD has a Quick Ratio of 1.59. This is a normal value and indicates that PMD is financially healthy and should not expect problems in meeting its short term obligations.

PMD's Quick ratio of 1.59 is fine compared to the rest of the industry. PMD outperforms 62.04% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.59
Quick Ratio	1.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.38% over the past year.

The Revenue for PMD has decreased by -11.15% in the past year. This is quite bad

The Revenue for PMD have been decreasing by -12.33% on average. This is quite bad

EPS 1Y (TTM)24.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.79%

Revenue 1Y (TTM)-11.15%

Revenue growth 3Y1.14%

Revenue growth 5Y-12.33%

Sales Q2Q%-9.21%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PMD. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

PMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PMD is cheaper than 65.74% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	32.63
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 12.67%, PMD is a good candidate for dividend investing.

Compared to an average industry Dividend Yield of 2.48, PMD pays a better dividend. On top of this PMD pays more dividend than 99.07% of the companies listed in the same industry.

PMD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.

		Industry Rank	Sector Rank
Dividend Yield	12.67%

5.2 History

The dividend of PMD decreases each year by -27.43%.

PMD has been paying a dividend for at least 10 years, so it has a reliable track record.

Dividend Growth(5Y)-27.43%

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

0.03% of the earnings are spent on dividend by PMD. This is a low number and sustainable payout ratio.

DP0.03%

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PSYCHEMEDICS CORP

NASDAQ:PMD (12/12/2024, 8:24:41 PM)

After market: 2.36 -0.31 (-11.61%)

2.67

-0.05 (-1.84%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Inst Owners20.49%

Inst Owner Change0%

Ins Owners12.5%

Ins Owner Change0%

Market Cap15.73M

Analysts100

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	12.67%

Yearly Dividend0.14

Dividend Growth(5Y)-27.43%

DP0.03%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.78
P/FCF	32.63
P/OCF	27.59
P/B	2.89
P/tB	2.89
EV/EBITDA	N/A

EPS(TTM)-0.51

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.08

FCFY3.06%

OCF(TTM)0.1

OCFY3.62%

SpS3.44

BVpS0.92

TBVpS0.92

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.45%
ROE	-54.99%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	38.36%
FCFM	2.38%

ROA(3y)-14.19%

ROA(5y)-10.61%

ROE(3y)-25.92%

ROE(5y)-19.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y18.48%

GM growth 5Y-4.66%

F-Score5

Asset Turnover2.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	1.21
Debt/EBITDA	N/A
Cap/Depr	6.99%
Cap/Sales	0.43%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.59
Quick Ratio	1.59
Altman-Z	0.82

F-Score5

WACC9.04%

ROIC/WACCN/A

Cap/Depr(3y)7.85%

Cap/Depr(5y)23.62%

Cap/Sales(3y)0.73%

Cap/Sales(5y)2.26%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)24.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%74.79%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-11.15%

Revenue growth 3Y1.14%

Revenue growth 5Y-12.33%

Sales Q2Q%-9.21%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-21.03%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-85.7%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-83.99%

OCF growth 3YN/A

OCF growth 5YN/A

PSYCHEMEDICS CORP (PMD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens